Skip to content

Revvity RVTY Impairment Charges

Impairment Charges at other companies

Danaher logo
DanaherDHR
$0-100%
Agilent Technologies logo
Agilent TechnologiesA
$15M
Zoetis logo
ZoetisZTS
$0-100%
Idexx Laboratories logo
Idexx LaboratoriesIDXX

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.

The official record: Revvity’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revvity's impairment charges?
Revvity (RVTY) reported impairment charges of $1.2M in Q4 2025.
How has Revvity's impairment charges changed year-over-year?
Revvity's impairment charges decreased by 79.0% year-over-year, from $5.7M to $1.2M.
What is the long-term trend for Revvity's impairment charges?
Over 3 years (2021 to 2025), Revvity's impairment charges has grown at a 7.3% compound annual growth rate (CAGR), from $3.87M to $4.78M.
What does impairment charges mean?
A non-cash expense recorded when an asset's value is written down.
How do you interpret impairment charges?
An increase suggests potential overvaluation of assets or deteriorating business prospects for specific segments.
How does impairment charges compare across companies?
Common across life science and diagnostic peers during periods of restructuring or post-acquisition integration.